FOXO1 and breast carcinoma: Similarly, in other cancer types including colorectal cancer, breast cancer and pancreatic cancer cell lines, GSK126 treatment also increased H3K27ac level but decreased H3K27me3 level in the FOXO1 promoter (Figure S2G, S2H).